Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma
Received 1 May 2020
Accepted for publication 5 October 2020
Published 10 November 2020 Volume 2020:12 Pages 11523—11526
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Antonella D'Anneo
Guohe Lin,1,* Bicheng Wang,2,* Xiuwei Wu,1 Tong Sun,1 Lili Chen,1 Canliang Lu,3 Nianfei Wang1
1Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China; 2Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of China; 3Department of Hepatopancreatobiliary Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Nianfei Wang
Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Furong Road No. 678, Hefei, Anhui 230601, People’s Republic of China
Department of Hepatopancreatobiliary Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Jixi Avenue No. 218, Hefei, Anhui 230022, People’s Republic of China
Purpose: Effective treatment options for intrahepatic cholangiocarcinoma (ICC) are limited. This study was intended to explore the efficacy and safety of apatinib in advanced ICC with lymph node metastasis or distant metastasis.
Patients and Methods: The efficacy and toxicity of apatinib were evaluated in patients with ICC between November 2017 and March 2020 at the Second Affiliated Hospital of Anhui Medical University. Survival analysis was estimated using Kaplan–Meier method.
Results: Ten patients with advanced ICC were enrolled. The median progression-free survival (PFS) was 3.0 months (95% CI: 1.450– 4.550). No patient achieved a complete response (CR). One patient gained partial response (PR), and 6 patients had stable disease (SD). The objective response rate (ORR) was 10%, and the disease control rate (DCR) was 70%. The common treatment-related adverse events were hypertension (20%), proteinuria (30%), hand and foot syndrome (10%) or emesis (10%). No grade 3/4 toxicities occurred. Toxicities were mild and tolerable.
Conclusion: Apatinib is potentially an effective treatment option with tolerable toxicities for patients with advanced ICC.
Keywords: intrahepatic cholangiocarcinoma, apatinib, efficacy, toxicity, progression-free survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]